o (G4C2)30+ transcription is mediated by Leo1 and Paf1 of the Paf1C The CDC73/PAF1 complex is recruited to elongating RNAPII at G4C2-repeats.
52
CDC73/PAF1 complex components Paf1 and Leo1 seem most important for RNAPII-53 driven transcription of expanded (G4C2)n, showing specificity to >30 G4C2 repeats in 54 flies. Further, PAF1 and LEO1 are upregulated in response to the expression of >30 55 G4C2 repeats in both the fly and in C9+ FTD patients due to increased requirements for 56 them. We hypothesize that this is the result of the expanded G4C2 DNA appropriating 57 Paf1/Leo1 along with RNAPII.
58

INTRODUCTION
59
In the C9orf72 gene, an intronic GGGGCC hexanucleotide (G4C2) expansion of 60 >30 repeats is the most prominent mutation in familial frontotemporal degeneration (FTD) 61 and amyotrophic lateral sclerosis (ALS) 1,2 . These devastating neurodegenerative 62 disorders represent a continuum of the same disease, while it remains unclear how one 63 patient presents with FTD and another with ALS or combined FTD/ALS [3] [4] [5] [6] .
64
While the presence of the expanded G4C2 can confer toxicity through a number 65 of aberrant pathways, amassing evidence supports contributions by gain-of-function 66 mechanisms [7] [8] [9] . Accumulation of sense strand G4C2-and antisense strand C4G2-
67
containing RNA results in RNA foci throughout the nervous system and may be toxic 10, 11 .
68
Further, these RNAs undergo repeat-associated non-AUG (RAN) translation to produce 69 dipeptide-repeats (DPRs) -GA, GR, GP, PA, and PR -which form potentially toxic 70 aggregates 12, 13 . Expressing expanded (G4C2)30+ repeat transcripts, independent of 71 changes to expression of the C9orf72 gene product, results in toxicity in multiple model 72 systems [7] [8] [9] . In Drosophila, expression of (G4C2)30+ transgenes results in the formation 73 of RNA foci and expression of DPRs, while causing neurodegenerative effects [14] [15] [16] [17] [18] [19] [20] [21] .
74
Repeat-expansions, including (G4C2)n, have been defined in a number of 75 neurodegenerative diseases 22, 23 . Toxicity associated with such mutations can result from 76 aberrant expression of the RNA and/or encoded peptides. As these mutations tend to be 77 GC-rich, they can form secondary structures (e.g. G-quadraplexes) and R-loops which 78 are thought to diminish RNAPII-driven transcription [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Specialized transcriptional 79 machinery may be required to promote the activity of RNAPII through long repeat 80 expansions. Of note, the DRB-sensitivity-inducing factor (DSIF) complex and the only a subset of cell-cycle genes are known to require its function for expression [45] [46] [47] [48] [49] [50] . In 90 the nervous system, PAF1C is critical to neural differentiation although it remains 91 expressed in mature neurons [51] [52] [53] [54] [55] [56] .
92
Here, we identified the components of PAF1C as modifiers of C9orf72-associated 93 disease in an unbiased, large scale RNAi-based screen for modifiers of (G4C2)49-toxicity 
RESULTS
102
RNA Polymerase II transcriptional complexes are enriched among suppressors of 103 (G4C2)49-toxicity.
104
To define cellular mechanisms underlying toxicity that occurs due to expression of 105 expanded (G4C2)30+ repeats in vivo, we designed a fly screen utilizing the degenerative 106 eye caused by (G4C2)49 expression with Gmr-GAL4 (Fig. 1a) . (G4C2) Fig. 1a-b) 20 . Overall, 119 115 modifiers of (G4C2)49-toxicity were identified, 55 suppressors and 64 enhancers (Fig.   116 1b).
117
To determine if these 119 modifiers were enriched for select processes, functions, 118 or components, gene ontology (GO) term analyses were performed 59, 60 . Enrichment 119 scores 61 were plotted for GO-terms that were significantly represented within our panel of 120 modifiers, p-value threshold of 10^-3 (Supplementary Fig. 1c ; Supplementary Data).
121
Strikingly, among suppressors, there was strong enrichment for genes associated with 122 RNAPII-driven transcription ( Fig. 1c; The CDC73/PAF1 complex is selective for toxicity from a G4C2-encoding RNA.
133
Expanded G4C2 RNA produces dipeptide-repeat proteins GR, GA, and GP in the fly 15-134 18 . Of these, (GR)30+ has been shown to be toxic in the eye of animals 15, 21 . As modifiers 135 of (G4C2)49-toxicity may be acting downstream of toxic GR-peptide production, we Overall, these data suggest that PAF1C suppression of (G4C2)49-toxicity is the 150 result of effects upstream of toxic-GR production.
152
The CDC73/PAF1 complex is selective for the G4C2 expansion. Fig. 2e ).
166
Taken together, these data highlight PAF1C selectivity towards (G4C2)49-167 associated toxicity. Supplementary Fig. 3a ).
175
Toxicity induced by expanded G4C2 repeat impacts the internal as well as the 176 external eye 20 . When PAF1C components were downregulated in eyes of (G4C2)49 177 expressing animals, internal retinal tissue loss was reduced ( Fig. 3a-b) . Notably, Paf1, (Fig. 3c-d) .
185
To examine effects of reduced expression of PAF1C components more broadly in 186 the fly nervous system on (G4C2)49-toxicity, we expressed the (G4C2)49 transgene 187 using a drug-inducible neuronal GAL4 driver, ElavGS. First, we assessed climbing ability 188 of animals. At 14d, only 62% of (G4C2)49 expressing animals were able to climb 4cm up 189 the wall of a vial within 20s (Fig. 3e) . Reduced expression of any of the PAF1C 190 components -Paf1, Leo1, CDC73, Ctr9, 191 such that climbing abilities were maintained at 90-100% (Fig. 3e) . Fig. 3f; Supplementary Fig. 4) . Further, the strong 199 suppressor CDC73 could increase survival of these animals, with 50% survival being
200
increased by 24h and the end time point being extended by 72h (Fig. 3g) . RNAi targeting We first asked if downregulation of PAF1C components -Paf1, Leo1, CDC73, 215 Ctr9, and Rtf1 -affected the amount of RNA produced from expanded (G4C2)49 in the 216 fly nervous system, using Spt4 RNAi as a positive control ( Fig. 4a; 
222
We determined if this effect was specific to the expanded (G4C2)49 transgene, by Fig. 4a; red) . To better understand how these numbers compared 230 among the three repeat lengths, data were plotted together allowing for statistical 231 comparisons between each (G4C2)n transcript levels with individual RNAi (Fig. 4a; top) . 
238
To determine if the reduced expression of G4C2-transgenes caused by PAF1C
239
RNAi was specific to the G4C2 construct, we examined the effects of knockdown on 240 expression of an alternative disease transgene, TDP43. TDP43 transcript levels were not 241 affected in the fly brain ( Fig. 4b; Supplementary Fig. 2e ). Further, we confirmed that 242 ubiquitous expression of PAF1C did not alter general RNAPII transcription, by examining 243 mRNA levels of endogenous housekeeping genes (Fig. 4c) 20, 41, 42, [45] [46] [47] [48] [49] [50] .
244
Effects of PAF1C RNAi could be the result of co-regulation of the components of 
257
Given the important role PAF1C is playing in (G4C2)49-expressing animals, we 258 considered that the complex may be dysregulated. To determine this, we examined the 259 15 expression from endogenous PAF1C genes -Paf1, Leo1, CDC73, Ctr9, animals expressing the (G4C2)49 repeat in the fly brain using a drug-inducible, neuronal 261 driver, ElavGS. Surprisingly, all components of PAF1C were upregulated (Fig. 5a ).
262
Compared to control, the steady state mRNA levels of Paf1 were increased by 69% 263 (SE±0.10), Leo1 by 58% (SE±0.13), CDC73 by 71% (SE±0.17), Ctr9 by 49% (SE±0.12),
264
and Rtf1 by 64% (SE±0.05). This upregulation was not seen upon expression of a short 265 (G4C2)8 repeat. Further, PAF1C upregulation appeared selective to the repeat expansion 266 as the transcript levels of PAF1C components were not upregulated in TDP43 expressing 267 animals, but rather downregulated (Fig. 5b) .
268
Taken together, these data indicated that PAF1C becomes upregulated in 269 response to expression of expanded G4C2 repeats in neurons. 
272
The fly data indicated that PAF1C is upregulated in response to expression of an 273 expanded G4C2 repeat in the brain and that PAF1C is required for expression of that 274 repeat. To better understand the role of PAF1C in disease, we extended studies to C9+ 275 FTD, FTD/ALS and ALS samples (patients that have >30 G4C2 repeats in C9orf72). We 276 focused on PAF1 and LEO1 as these PAF1C components selectively regulated 277 expression of the longer G4C2 repeat in Drosophila.
278
RNA was extracted from frontal cortex tissue of C9+ patients (n=67), C9-patients 279 (n=56), or healthy controls (n=27) and the level of PAF1 and LEO1 expression were 280 assessed by qPCR ( Fig. 6a; Supplementary Fig. 5a ). In patients diagnosed with FTD,
281
PAF1 and LEO1 were significantly upregulated only when the repeat expansion was (Fig. 6b) . No correlations were observed in C9-FTD cases or in healthy 305 17 controls. In C9+ ALS cases, no correlations were observed between PAF1 or LEO1 levels 306 compared to the level of repeat-containing C9orf72 transcript and C9-ALS cases showed 307 a relatively weaker correlation than that observed for C9+ FTD (Supplementary Fig. 5b ).
308
In summary, these data support that PAF1 and LEO1 expression positively Further, extended studies in patients showed that PAF1 and LEO1 were upregulated in 326 FTD patients only when they carried the expanded repeat in C9orf72. This upregulation 327 positively correlated with expression of the repeat-containing C9orf72, supporting a 328 mechanistic link between PAF1C levels, expression of a G4C2-repeat, and C9+ disease.
329
A total of 119 modifiers of (G4C2)49-toxicity were identified in our RNAi-based 330 screen (Fig 1; Supplementary Data) were prominent. Curiously, the majority of these enhancers similarly modulate (GR)36-338 toxicity (Fig. 2) . These data are consistent with reports of RNA dysregulation and splicing 339 deficits in C9+ FTD/ALS, while suggesting that disruptions in RNA metabolism may result 340 from toxic GR 80 .
341
RNAPII-driven transcription across GC-rich DNA is hypothesized to be difficult due 342 to the propensity of the DNA to form secondary structures, such as R-loops and G-343 quadraplexes [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Given this, the activity of multiple elongation factors may be required 344 for efficient transcription through expansions like (G4C2)30+. Spt4 was previously 345 implicated as a transcriptional regulator of CAG and G4C2 repeat expansions in 346 disease 20, 43, 44 . Our data indicates that PAF1C is also critical for mediating expression of 347 G4C2 repeats in FTD/ALS (Fig. 4) . Paf1 and Leo1 of PAF1C seem particularly important 348 for RNAPII-transcription of expanded G4C2 as loss of these two components selectively 349 results in reduced expression of a (G4C2)49 transgene in the fly (Fig. 4) . Consistent with 350 their having similar effects on (G4C2)49 expression, these two components form a 351 heterodimer that is important for PAF1C activation of elongating RNAPII 37, 49, 81, 78, [82] [83] [84] .
352
In contrast to Paf1/Leo1, Spt4 showed similar effects on different G4C2 repeat 353 lengths, an unexpected result given previous findings (Fig. 4) in mammals 46, 48, [90] [91] [92] . Further, PAF1C directly interacts with elongating RNAPII 81 .
364
Together, data suggests that PAF1C is playing a unique role in transcription elongation 365 across a G4C2-repeat expansion.
366
FTD and ALS represent a spectrum of the same disease while overlap may be the 367 result of unique genetic backgrounds of individuals [4] [5] [6] [75] [76] [77] . To date, only Ataxin-2 has 368 been suggested as a disease modifier underlying the different diagnoses 3 . We see 369 upregulation of PAF1 and LEO1 in the frontal cortex of C9+ FTD, but not C9+ ALS cases 370 compared to C9-cases and healthy controls (Fig. 6) . Importantly, the frontal cortex is 371 thought to be a primary brain region resulting in FTD-associated symptoms 75, 76, 93 .
372
Further, C9+ FTD/ALS cases have lower levels of upregulation of PAF1 and LEO1 than 373 C9+ FTD cases, supporting that these would fall between FTD only and ALS only disease.
374
Patient data were consistent with fly data, as flies expressing (G4C2)49 showed 375 upregulation of endogenous PAF1C components (Fig. 5) . Overall, it is tempting to 376 hypothesize that modulation of Paf1 or Leo1 may be among a number of mechanisms 377 contributing to the onset of different disease phenotypes in C9orf72-associated disease.
378
PAF1C may be an attractive therapeutic candidate for C9+ FTD. In yeast, PAF1C 379 has been reported to be non-essential 20, 41, 43 . In the fly, Leo1 has also been shown to be 380 non-essential 94 . In mice, PAF1 +/-or LEO1 +/-heterozygosity yields no obvious 381
